Answer
Women of childbearing potential should use effective contraception during belatacept treatment and up to 8 weeks after the last dose because the potential risk to embryonic or foetal development is unknown.
Sources for this answer
- NULOJIX 250 mg powder for concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 17Document updated
Sources checked